Regeneron Pharmaceuticals, Inc experienced a somewhat steady performance in the stock market. The company’s stock reached a 1-year high of $1211.20 on 08/27/24, while the lowest price for the same period was registered at $772.84 on 10/31/23.
52-week price history of REGN Stock
Studying a stock’s 52-week price history, which includes both low and high prices, can help gauge its current status and potential future performance. Regeneron Pharmaceuticals, Inc’s current trading price is -30.80% away from its 52-week high, while its distance from the 52-week low is 8.46%. The stock’s price range during the 52-week period has remained between $772.84 and $1211.20. In the Healthcare sector, the company’s shares saw a trading volume of around 2.28 million for the day, which was evidently higher than the average daily volume of 0.6 million over the past three months.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Market Capitalization and Financial Performance: An In-Depth Look
Regeneron Pharmaceuticals, Inc (REGN) has experienced a quarterly decline of -22.55% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 92.38B and boasts a workforce of 13450 employees.
Making Sense of Trading Volume and Moving Average Data
Based on Barchart.com data, the company’s moving average over the 100-day period was 1,073.34, with a change in price of -163.53. Similarly, Regeneron Pharmaceuticals, Inc recorded 562,152 in trading volume during the last 100 days, posting a change of -16.32%.
Examining REGN’s Debt-to-Equity Ratio: What You Need to Know
The debt-to-equity (D/E) ratio is a crucial measure that sheds light on a company’s financial health and market standing. It is determined by dividing a company’s overall liabilities by its shareholders’ equity, showing the extent of a company’s debt usage in financing its assets compared to the shareholders’ equity. At the time of writing, the total D/E ratio for REGN stands at 0.10. Similarly, the long-term debt-to-equity ratio is also 0.10.
REGN Stock Stochastic Average
As of today, Regeneron Pharmaceuticals, Inc’s raw stochastic average for the last 50 days stands at 5.62%. This is a decline compared to the raw stochastic average of the previous 20 days, which was noted at 10.66%. Furthermore, the company’s Stochastic %K and %D values for the past 20 days were 7.77% and 7.19%, respectively.
REGN Stock Price Performance Analysis
The stock price’s performance over the year has been unpredictable, resulting in a mix of pessimistic and optimistic outlooks among investors. The index has shown a price loss of -4.56% this year. Over the last six months, there has been a stronger performance of -10.60%. The price of REGN leaped by -19.42% during the last 30 days period. For the last 5-days stocks have slided -9.76%.
